Gil Awada

1.0k total citations
58 papers, 691 citations indexed

About

Gil Awada is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gil Awada has authored 58 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Gil Awada's work include Cancer Immunotherapy and Biomarkers (33 papers), Melanoma and MAPK Pathways (15 papers) and Brain Metastases and Treatment (11 papers). Gil Awada is often cited by papers focused on Cancer Immunotherapy and Biomarkers (33 papers), Melanoma and MAPK Pathways (15 papers) and Brain Metastases and Treatment (11 papers). Gil Awada collaborates with scholars based in Belgium, United States and Netherlands. Gil Awada's co-authors include Bart Neyns, Julia Katharina Schwarze, Ahmad Awada, Anne Rogiers, Hampig Raphaël Kourié, Hendrik Everaert, Teofila Seremet, Yanina Jansen, Jennifer Cremer and Peter Theuns and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Endocrinology.

In The Last Decade

Gil Awada

53 papers receiving 682 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gil Awada Belgium	15	450	176	156	151	132	58	691
Ebenezer A. Kio United States	10	350 0.8×	255 1.4×	85 0.5×	269 1.8×	83 0.6×	29	711
Hidenori Mizugaki Japan	14	400 0.9×	207 1.2×	72 0.5×	231 1.5×	38 0.3×	40	710
Heather M. Shaw United Kingdom	13	352 0.8×	349 2.0×	93 0.6×	132 0.9×	55 0.4×	34	725
J.M. Sánchez-Torres Spain	13	614 1.4×	150 0.9×	99 0.6×	428 2.8×	42 0.3×	21	772
Ciara C. O’Sullivan United States	18	590 1.3×	293 1.7×	67 0.4×	262 1.7×	114 0.9×	72	1.0k
Unn‐Merete Fagerli Norway	13	278 0.6×	286 1.6×	77 0.5×	50 0.3×	138 1.0×	33	744
Samanta Sarti Italy	17	490 1.1×	205 1.2×	60 0.4×	193 1.3×	37 0.3×	46	803
Todd Riehl United States	13	431 1.0×	288 1.6×	58 0.4×	284 1.9×	60 0.5×	28	831
Gian Carlo Antonini Cappellini Italy	15	807 1.8×	355 2.0×	259 1.7×	261 1.7×	53 0.4×	25	1.1k
Yasushi Otani Japan	10	383 0.9×	149 0.8×	50 0.3×	171 1.1×	78 0.6×	19	607

Countries citing papers authored by Gil Awada

Since Specialization

Citations

This map shows the geographic impact of Gil Awada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gil Awada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gil Awada more than expected).

Fields of papers citing papers by Gil Awada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gil Awada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gil Awada. The network helps show where Gil Awada may publish in the future.

Co-authorship network of co-authors of Gil Awada

This figure shows the co-authorship network connecting the top 25 collaborators of Gil Awada. A scholar is included among the top collaborators of Gil Awada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gil Awada. Gil Awada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alawadi, Fatheya, Fouzia Rashid, Gil Awada, et al.. (2025). Prevalence of cardiovascular risk and atherosclerotic cardiovascular disease in people with type 2 diabetes in the United Arab Emirates: Results from the prevalence of atherosclerotic cardiovascular disease in patients with type 2 diabetes across Middle East and African countries (PACT-MEA) study. Diabetes & Metabolic Syndrome Clinical Research & Reviews. 19(4). 103224–103224. 1 indexed citations

Bashier, Alaaeldin, et al.. (2025). Achievement of guideline targets among people with type 2 diabetes with eASCVD and high risk of ASCVD in the UAE: Results of the PACT-MEA-UAE cohort. Diabetes Research and Clinical Practice. 221. 112030–112030.

Awada, Gil, Tina Cascone, Michiel S. van der Heijden, et al.. (2025). The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types. Nature Cancer. 6(6). 967–987. 6 indexed citations

Awada, Gil, et al.. (2024). Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report. Frontiers in Medicine. 11. 1436774–1436774. 1 indexed citations

Awada, Gil, et al.. (2024). Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAF^V600/NRAS^Q61 Wild-Type Melanoma (TraMel-WT). JCO Precision Oncology. 8(8). e2300493–e2300493. 4 indexed citations

Awada, Gil, et al.. (2023). Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study. Journal of Clinical Medicine. 12(3). 1214–1214. 2 indexed citations

Awada, Gil. (2022). Melanoma with genetic alterations beyond the BRAFV600 mutation. VUBIR (Vrije Universiteit Brussel). 6 indexed citations

Awada, Gil. (2022). A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. VUBIR (Vrije Universiteit Brussel). 16 indexed citations

Jansen, Yanina, Astrid A.M. van der Veldt, Gil Awada, & Bart Neyns. (2022). Anti-PD-1: When to Stop Treatment. Current Oncology Reports. 24(7). 905–915. 11 indexed citations

10.

Neyns, Bart, Jürgen Schwarze, Gil Awada, et al.. (2021). 342O Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial. Annals of Oncology. 32. S516–S517. 1 indexed citations

11.

Awada, Gil, et al.. (2021). Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report. BMC Ophthalmology. 21(1). 250–250. 14 indexed citations

12.

Schwarze, Julia Katharina, et al.. (2021). C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. Melanoma Research. 31(4). 371–377. 16 indexed citations

13.

Rogiers, Anne, Christophe Leys, Adrian Schembri, et al.. (2020). Neurocognitive Function, Psychosocial Outcome, and Health‐Related Quality of Life of the First‐Generation Metastatic Melanoma Survivors Treated with Ipilimumab. Journal of Immunology Research. 2020(1). 2192480–2192480. 31 indexed citations

14.

Awada, Gil, et al.. (2020). Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1. Case Reports in Oncology. 13(2). 1031–1036. 7 indexed citations

15.

Rogiers, Anne, Jennifer Cremer, Gil Awada, et al.. (2019). Emotional disturbances, social outcome and neurocognitive function in advanced melanoma survivors treated with pembrolizumab. Journal of Translational Medicine. 17. 7. 1 indexed citations

16.

Seremet, Teofila, Yanina Jansen, H. Njimi, et al.. (2019). Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. Journal of Translational Medicine. 17(1). 303–303. 96 indexed citations

17.

Awada, Gil, Evandro de Azambuja, & Ahmad Awada. (2017). Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients. Expert Opinion on Drug Metabolism & Toxicology. 13(12). 1205–1215. 1 indexed citations

18.

Kourié, Hampig Raphaël, Gil Awada, & Ahmad Awada. (2016). Rare side-effects of checkpoint inhibitors. Current Opinion in Oncology. 28(4). 295–305. 7 indexed citations

19.

Awada, Gil, Andrea Gombos, Philippe Aftimos, & Ahmad Awada. (2016). Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer. Expert Opinion on Emerging Drugs. 21(1). 91–101. 26 indexed citations

20.

Kourié, Hampig Raphaël, Gil Awada, & Ahmad Awada. (2016). Learning from the “tsunami” of immune checkpoint inhibitors in 2015. Critical Reviews in Oncology/Hematology. 101. 213–220. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact